122 related articles for article (PubMed ID: 34882822)
1. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients.
Adie SK; Bitar A; Konerman MC; Dorsch MP; Andrews CA; Pogue K; Park JM
Pharmacotherapy; 2022 Feb; 42(2):106-111. PubMed ID: 34882822
[TBL] [Abstract][Full Text] [Related]
2. Early Monitoring and Subsequent Gain of Tacrolimus Time-In-Therapeutic Range May Improve Clinical Outcomes After Living Kidney Transplantation.
Yin S; Huang Z; Wang Z; Fan Y; Wang X; Song T; Lin T
Ther Drug Monit; 2021 Dec; 43(6):728-735. PubMed ID: 34780391
[TBL] [Abstract][Full Text] [Related]
3. Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients.
Leino AD; Park JM; Pasternak AL
Pharmacotherapy; 2021 Aug; 41(8):649-657. PubMed ID: 34129685
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus time-in-therapeutic range is associated with freedom from acute rejection and graft failure following intestinal transplantation.
Santeusanio AD; Gu A; Weinberg AD; Moon J; Iyer KR
Clin Transplant; 2021 Jun; 35(6):e14291. PubMed ID: 33740822
[TBL] [Abstract][Full Text] [Related]
5. Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation.
Song T; Yin S; Jiang Y; Huang Z; Liu J; Wang Z; Li L; Zeng J; Fan Y; Wang X; Li X; Lin T
Front Immunol; 2019; 10():2912. PubMed ID: 31921171
[No Abstract] [Full Text] [Related]
6. Association Between Time-in-Therapeutic Tacrolimus Range and Early Rejection After Heart Transplant.
Baker WL; Steiger S; Martin S; Patel N; Radojevic J; Darsaklis K; O'Bara L; Kutzler H; Dougherty J; Feingold A; Hammond J; Fusco D; Gluck JA
Pharmacotherapy; 2019 May; 39(5):609-613. PubMed ID: 30892740
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
Solomon S; Colovai A; Del Rio M; Hayde N
Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
[TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Tacrolimus Time in Therapeutic Range and Intrapatient Variability in Urban Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal.
Pierce DR; West-Thielke P; Hajjiri Z; Gaitonde S; Tzvetanov I; Benedetti E; Lichvar AB
Transplant Direct; 2021 Jun; 7(6):e698. PubMed ID: 34036168
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
[TBL] [Abstract][Full Text] [Related]
10. Lower tacrolimus time in therapeutic range is associated with inferior outcomes in adult liver transplant recipients.
Song W; Lao Q; Hu J; Li D; Du Y; Zhu H
Basic Clin Pharmacol Toxicol; 2023 Jan; 132(1):51-59. PubMed ID: 36197905
[TBL] [Abstract][Full Text] [Related]
11. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus: in heart transplant recipients.
McCormack PL; Keating GM
Drugs; 2006; 66(17):2269-79; discussion 2280-2. PubMed ID: 17137409
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a Standardized Tacrolimus Therapeutic Drug Monitoring Protocol in Stable Kidney Transplant Recipients.
Ky TQ; Silas NP; Taylor RM; Barakat AO; Harb R; Laviste NC; Park JM
Prog Transplant; 2022 Sep; 32(3):212-218. PubMed ID: 35695240
[No Abstract] [Full Text] [Related]
14. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
[TBL] [Abstract][Full Text] [Related]
15. Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients.
Singh TP; Faber C; Blume ED; Worley S; Almond CS; Smoot LB; Dillis S; Nasman C; Boyle GJ
J Heart Lung Transplant; 2010 May; 29(5):517-22. PubMed ID: 20061164
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
17. Impact of a pharmacist-led tacrolimus management protocol in the outpatient setting.
Owen K; Winters H; Palettas M; Witkowsky O
J Am Pharm Assoc (2003); 2022; 62(6):1912-1918. PubMed ID: 35843802
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus: a further update of its use in the management of organ transplantation.
Scott LJ; McKeage K; Keam SJ; Plosker GL
Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
[TBL] [Abstract][Full Text] [Related]
20. Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation.
Katada Y; Nakagawa S; Itohara K; Suzuki T; Kato R; Endo H; Sugimoto M; Yonezawa A; Nakagawa T; Ohsumi A; Nakajima D; Date H; Terada T
J Pharm Health Care Sci; 2022 Oct; 8(1):25. PubMed ID: 36180948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
